A meta-analysis of patients with pretreated microsatellite instability-high (MSI-H) cancers treated with immune checkpoint inhibitors (ICIs), published in JAMA Oncology, found that ICIs were correlated with high activity, independent of tumor type and drug used.
Additionally, the researchers suggested that among molecular biomarkers for selection of treatment, mismatch repair (MMR) proteins may have a predictive value for the activity of immunotherapy.
“Although not currently approved worldwide, according to these findings anti-PD-(L)1 agents represent a potentially important treatment option for (deficient mismatch repair [dMMR]/MSI-H) tumors,” the authors wrote.
Researchers used published articles that evaluated ICIs in the treatment of advanced MSI-H tumors from inception to December 2019; articles were identified by searching the PubMed, EMBASE, and Cochrane Library…
